Sandbox: sadaf: Difference between revisions
Jump to navigation
Jump to search
Line 427: | Line 427: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | ! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Infection''' | ||
! rowspan="2" align="center" style="background:#DCDCDC;" + |'''Viral infections''' | |||
! align="center" style="background:#DCDCDC;" + |'''Viral infections | |||
rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | !rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 478: | Line 453: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!'''HIV''' | |||
!'''HIV''' | |||
! | ! | ||
* Direct toxicity to megakaryocytes | * Direct toxicity to megakaryocytes | ||
Line 506: | Line 479: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! | ! rowspan="3" |Bacterial infections | ||
!'''Sepsis''' | !'''Sepsis''' | ||
!Direct bone marrow suppression | !Direct bone marrow suppression | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 531: | Line 503: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Helicobacter pylori | !Helicobacter pylori | ||
!Immune thrombocytopenia | !Immune thrombocytopenia | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 556: | Line 526: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections | !leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 581: | Line 549: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="2" |'''Intracellular parasites''' | ! rowspan="2" |'''Intracellular parasites''' | ||
!Malaria | !Malaria | ||
Line 606: | Line 573: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Babesiosis | !Babesiosis | ||
| | | | ||
Line 630: | Line 596: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!Medications | ! rowspan="6" |Medications/toxicity | ||
!'''Drug-induced immune thrombocytopenia''' | !'''Drug-induced immune thrombocytopenia''' | ||
! | ! | ||
Line 665: | Line 631: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!'''Heparin-induced thrombocytopenia''' | !'''Heparin-induced thrombocytopenia''' | ||
! | ! | ||
Line 690: | Line 655: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!'''Cytotoxic chemotherapy''' | !'''Cytotoxic chemotherapy''' | ||
! | ! | ||
Line 715: | Line 679: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!'''Radiation therapy''' | !'''Radiation therapy''' | ||
! | ! | ||
Line 740: | Line 703: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
!OTC agents | !OTC agents | ||
!Quinine-containing beverages | !Quinine-containing beverages | ||
Line 765: | Line 727: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |'''Alcohol''' | ! align="center" style="background:#DCDCDC;" + |'''Alcohol''' | ||
! | ! | ||
Line 1,034: | Line 971: | ||
! | ! | ||
|- | |- | ||
!'''Rheumatologic/autoimmune disorders''' | |||
!Systemic lupus erythematosus (SLE) | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
! | |||
!Antiphospholipid syndrome (APS) | |||
! | |||
!autoantibody-mediated syndrome | |||
! | ! | ||
! | ! | ||
Line 1,059: | Line 1,021: | ||
! | ! | ||
|- | |- | ||
! | |||
!Felty's syndrome | |||
! | |||
!splenomegaly | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
! | ! | ||
! | ! | ||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
! rowspan="3" |vascular | |||
!giant capillary hemangioma, | |||
! | |||
!platelet destruction | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
!large aortic aneurysms, | |||
! | |||
!platelet destruction | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
!cardiopulmonary bypass | |||
! | |||
!platelet destruction | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! | |||
|- | |||
! | |||
!Post-transfusion purpura | |||
! | |||
!immune-mediated platelet destruction | |||
! | ! | ||
! | ! |
Revision as of 18:42, 7 August 2018
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | ||||||||||||||||||||||
Lab Findings | Imaging | ||||||||||||||||||||||
Severity | Fever | Bleeding | BP | Other | CBC | PBS | Coagulopathy | ||||||||||||||||
Mechanism | |||||||||||||||||||||||
Infectious diseases | Gestational thrombocytopenia | ||||||||||||||||||||||
Chronic liver disease | |||||||||||||||||||||||
portal hypertension | |||||||||||||||||||||||
Hypersplenism | |||||||||||||||||||||||
Immune thrombocytopenia | Antibody-mediated platelet destruction | Moderate to severe | - | Diagnosis of exclusion | |||||||||||||||||||
Congenital platelet disorders | MYH-9 related disorders | ||||||||||||||||||||||
Bernard-Soulier syndrome | |||||||||||||||||||||||
Gray platelet syndrome | |||||||||||||||||||||||
Wiskott-Aldrich syndrome | |||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | |||||||||||||||||||||||
Alport syndrome | |||||||||||||||||||||||
Von Willebrand disease | |||||||||||||||||||||||
Infection | Viral infections | rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | |||||||||||||||||||||
HIV |
|
||||||||||||||||||||||
Bacterial infections | Sepsis | Direct bone marrow suppression | |||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | ||||||||||||||||||||||
leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections | |||||||||||||||||||||||
Intracellular parasites | Malaria | ||||||||||||||||||||||
Babesiosis | |||||||||||||||||||||||
Medications/toxicity | Drug-induced immune thrombocytopenia |
|
Occurrence of drug-dependent, platelet-reactive antibodies | ||||||||||||||||||||
Heparin-induced thrombocytopenia | |||||||||||||||||||||||
Cytotoxic chemotherapy | |||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | ||||||||||||||||||||||
OTC agents | Quinine-containing beverages | ||||||||||||||||||||||
Alcohol | |||||||||||||||||||||||
Malignancy | |||||||||||||||||||||||
Nutrient deficiencies | folate, vitamin B12, copper | an autoimmune mechanism | Mild | ||||||||||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | ||||||||||||||||||||||
Hemolytic uremic syndrome (HUS) | |||||||||||||||||||||||
Drug-induced TMA (DITMA) | |||||||||||||||||||||||
Bone marrow disorders | Myelodysplastic syndromes | ||||||||||||||||||||||
Aplastic anemia | |||||||||||||||||||||||
Acute leukemia | |||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | |||||||||||||||||||||||
Rheumatologic/autoimmune disorders | Systemic lupus erythematosus (SLE) | ||||||||||||||||||||||
Antiphospholipid syndrome (APS) | autoantibody-mediated syndrome | ||||||||||||||||||||||
Felty's syndrome | splenomegaly | ||||||||||||||||||||||
vascular | giant capillary hemangioma, | platelet destruction | |||||||||||||||||||||
large aortic aneurysms, | platelet destruction | ||||||||||||||||||||||
cardiopulmonary bypass | platelet destruction | ||||||||||||||||||||||
Post-transfusion purpura | immune-mediated platelet destruction |